A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age
Latest Information Update: 03 Mar 2026
At a glance
- Drugs MRNA-1403 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms NOVA-301
- Sponsors Moderna Therapeutics
Most Recent Events
- 25 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2026 According to a Moderna media release, company is enrolling patients in a second Northern Hemisphere season (2025-2026) for additional case accruals, which will inform the timing of the phase 3 readout. And, the company expects an interim analysis in 2026.
- 26 Nov 2025 Planned number of patients changed from 25000 to 28000.